Search results
Doctor Who 'Rogue': Who is the eponymous Rogue?
SPACE.com· 2 days agoIn "Rogue," the latest episode of "Doctor Who," the Doctor and Ruby Sunday travel to the 19th century to enjoy the delights of Regency England. The...
Taylor Swift fans are calling COVID infections from concerts "souvenirs"
Newsweek· 2 days agoTaylor Swift fans have sparked uproar by describing COVID-19 as a "souvenir" after a number of them reportedly contracted the virus during the singer's recent concerts in Madrid. About 130,000 ...
Obituaries in Asheville, NC | Asheville Citizen-Times
Asheville Citizen-Times· 4 days agoHenry Dayton Wilde, Jr., 93, left his earthly life on June 3, 2024, at Highland Farms in Black...
2-in-1 shot for flu and COVID shows promise in advanced trial
LiveScience· 4 days agoAn experimental two-in-one vaccine triggered strong immune responses against both the flu and SARS-CoV-2, the virus behind COVID-19, in an advanced clinical trial that included adults ages 50 ...
Is There a New COVID Booster to Prevent Against FLiRT Variants?
Good Housekeeping· 6 days agoA lot has happened with COVID-19 vaccines in the past few years, making it difficult to keep up....
Moderna's combination Covid, flu vaccine is more effective than existing shots in late-stage trial
NBC Miami· 5 days agoModerna said its combination vaccine targeting Covid and the flu was more effective than existing...
Texas eviction filings among the nation's highest as millions of rent relief dollars go unspent
KRGV Rio Grande Valley· 2 days agoSign up for The Brief, our daily newsletter that keeps readers up to speed on the most essential...
Pershing Resources Names Patrick J. Burns as Director of Project Development
Digital Journal· 5 days agoRENO, NV / ACCESSWIRE / June 10, 2024 / Pershing Resources Company Inc., (OTCPK:PSGR), is pleased to announce that Mr. Patrick J. Burns has taken an executive role with the Company and will ...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation...
Morningstar· 2 days agoCAMBRIDGE, MA / ACCESSWIRE / June 13, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that its Phase 3 trial of mRNA-1283, an investigational next-generation COVID-19 vaccine, has met its ...
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Digital Journal· 5 days agomRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an ...